Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 2;10(42):4255-4261.
doi: 10.18632/oncotarget.26981.

Modified Simon's minimax and optimal two-stage designs for single-arm phase II cancer clinical trials

Affiliations

Modified Simon's minimax and optimal two-stage designs for single-arm phase II cancer clinical trials

Jongphil Kim et al. Oncotarget. .

Abstract

Simon's two-stage design and the admissible two-stage design have been commonly used in practice for single-arm phase II clinical trials when the primary endpoint is binary. The ethical benefit of the two-stage design over the single-stage design is attained by the early termination of the trial when the treatment seems to be inactive. While Simon's optimal design is the two-stage design that minimizes the expected number of subjects under the null hypothesis, the probability of falsely declaring futility after the first stage frequently seems undesirably high. In Simon's minimax design, however, it is often the case that a high proportion of the total planned subjects are evaluated in the first stage, and thus the ethical benefit may not be achieved. In this paper, we propose modified minimax and optimal two-stage designs which guarantee not only type I and II error rates but also reasonable sample size proportions in the first stage, while maintaining the probability of falsely declaring futility under a pre-selected level. The characteristics of the modified two-stage design will be compared with those of Simon's and the admissible two-stage design. The modified minimax design yields a design that requires modest increase in 29% of cases, while the modified optimal design saves 1 to 13 subjects in 81% of cases for β = 0.2. The modified design approach provides investigators with an alternative when the sample sizes of Simon's designs are severely unbalanced or the Type II error is unacceptably high after the first stage.

Keywords: Simon’s two-stage design; admissible two-stage design; binary endpoint; modified two-stage design; single-arm phase ii clinical trials.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST The authors report no relevant conflicts of interest.

Figures

Figure 1
Figure 1
Comparisons of total sample sizes between modified designs with γ1 = 1/3, γ2 = 2/3, and ε = 0.1 and Simon’s designs for p1 – p0 = 0.2 (A) and p1 – p0 = 0.15 (B). The top panels of A and B show the number of additional subjects required for the modified minimax designs while the bottom panels indicate those for modified optimal designs.
Figure 2
Figure 2
Simon’s minimax (top two panels) and Simon’s optimal designs (bottom two panels) for p1 - p0 = 0.15 and 0.2: ratio of n1 to n (left panels) and the type II error spent in the first stage (PET1, right panels) for (α, β) = (0.05, 0.2).

Similar articles

Cited by

References

    1. Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Le Blanc M, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res. 2010; 16:1764–69. 10.1158/1078-0432.CCR-09-3287. - DOI - PMC - PubMed
    1. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis. 1961; 13:346–53. 10.1016/0021-9681(61)90060-1. - DOI - PubMed
    1. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10:1–10. 10.1016/0197-2456(89)90015-9. - DOI - PubMed
    1. Herndon JE., 2nd A design alternative for two-stage, phase II, multicenter cancer clinical trials. Control Clin Trials. 1998; 19:440–50. 10.1016/S0197-2456(98)00012-9. - DOI - PubMed
    1. Ye F, Shyr Y. Balanced two-stage designs for phase II clinical trials. Clin Trials. 2007; 4:514–24. 10.1177/1740774507084102. - DOI - PubMed

LinkOut - more resources